This sentiment is seen as potentially beneficial for Arcellx's anito-cel, which may gain market adoption due to its more favorable toxicity profile. The company's strong balance sheet, with more ...

The company presented promising preliminary data from its Phase 2 pivotal iMMagine-1 study at the ASH 2024, showcasing the potential of its anito-cel therapy for patients with relapsed or ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...